EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

China special issue on gastrointestinal tumors‐Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD ‐1 blockade: A post hoc analysis of the PICC phase II trial

Wuteng Cao iD, Huabin Hu iD, Jiao Li iD, Qianyu Wu iD, Lishuo Shi iD, Biao Li iD, Jie Zhou iD, Xinhua Wang iD, Junhong Chen iD, Chao Wang iD, Huaiming Wang iD, Weihao Deng iD und 2 weitere

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34647 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Wuteng Cao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Colonic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant programmed cell death protein 1 (PD‐1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD‐1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non‐pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non‐pCR tumors. Additionally, a higher proportion of the absence of vascular sign ( P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357‐493.110]), nodular sign ( P < .001, OR = 189.000 [95% CI, 10.464‐3413.803]) and extramural enhancement sign ( P = .003, OR = 21.667 [2.848‐164.830]) was observed in tumors with pCR. In conclusion, these CT‐defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD‐1 blockade, particularly in individuals who are willing to adopt a watch‐and‐wait strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsColonic NeoplasmsDNA Mismatch RepairBrain NeoplasmsNeoplastic Syndromes, HereditaryProgrammed Cell Death 1 ReceptorNeoadjuvant TherapyHumans

Stichwörter der Autor:innen

colorectal cancercomputed tomographyneoadjuvant PD-1 blockadepathological complete response

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Clinical Research Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, China.

ORCID-Profile: Wuteng Cao, Huabin Hu, Jiao Li, Qianyu Wu, Lishuo Shi, Biao Li, Jie Zhou, Xinhua Wang, Junhong Chen, Chao Wang, Huaiming Wang, Weihao Deng, Yan Huang, Yanhong Deng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cao, W., Hu, H., Li, J., Wu, Q., Shi, L., Li, B., Zhou, J., Wang, X., Chen, J., Wang, C., Wang, H., Deng, W., Huang, Y., & Deng, Y. (2023). China special issue on gastrointestinal tumors‐Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD ‐1 blockade: A post hoc analysis of the PICC phase II trial. International Journal of Cancer. https://doi.org/10.1002/ijc.34647

Vancouver

Cao W, Hu H, Li J, Wu Q, Shi L, Li B, et al. China special issue on gastrointestinal tumors‐Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD ‐1 blockade: A post hoc analysis of the PICC phase II trial. International Journal of Cancer. 2023. doi:10.1002/ijc.34647

BibTeX
@article{Cao2023,
  author = {Cao, Wuteng and Hu, Huabin and Li, Jiao and Wu, Qianyu and Shi, Lishuo and Li, Biao and Zhou, Jie and Wang, Xinhua and Chen, Junhong and Wang, Chao and Wang, Huaiming and Deng, Weihao and Huang, Yan and Deng, Yanhong},
  title = {China special issue on gastrointestinal tumors‐Radiological features of pathological complete response in mismatch repair deficient colorectal cancer after neoadjuvant PD ‐1 blockade: A post hoc analysis of the PICC phase II trial},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34647}
}
Kostenlos starten →